nano-congress-2016_posters-accepted-abstracts

3 / 17

Volume 7, Issue 4(Suppl) J Nanomed Nanotechnol
ISSN: 2157-7439 JNMNT, an open access journal
Page 67
Notes:
Nano Congress 2016
August 01-02, 2016
conferenceseries.com
August 01-02, 2016 Manchester, UK
9th Nano Congress for Next Generation
Anewfluorescence/PETprobe for intracellular human telomerase reverse transcriptase (hTERT) using
Tat peptide-conjugated IgM antibody
Kyung Oh Jung
Seoul National University College of Medicine, Korea
Human Telemorase Reverse Transcriptase, hTERT, is expressed in most cancer cells, and considered as an important tumor
biomarker. However, targeting hTERT is difficult due to its cellular location. We developed a new dual probe for optical and
nuclear imaging to visualize intracellular hTERT proteins using Tat peptide-conjugated IgM antibody. Monoclonal IgM antibodies
for hTERT were conjugated with the Tat peptide, fluorescence dye (FPR648) and 64Cu-NOTA. HT29 (hTERT+) and U2OS (hTERT-)
cells were imaged by confocal microscopy and analyzed by Tissue-FAXS. To visualize nuclear transport of hTERT, tumor cells were
irradiated with 4 Gy of ionizing radiation. Tumor xenografts were visualized using Maestro and PETBOX. Cellular penetration was
improved by Tat peptide and retention time was prolonged with IgM antibody as compared to IgG antibody. More fluorescence signals
were detected in HT29 cells than in U2OS cells after 24 hr. Strong positive fluorescence signals were observed in 78.54% of total HT29
cells. Interestingly, this probe could visualize nuclear transport of hTERT after irradiation. Fluorescence and PET images of the mice
clearly showed higher fluorescence signals and radioactivities in HT29 tumors than in U2OS tumors. In tissues, fluorescence signals
were only detected in HT29 tumors. We developed a new fluorescence/PET probe for visualizing the intracellular hTERT using the
Tat conjugated antibody which improved cellular penetration. This system can be applied to visualize other intracellular proteins and
also can be used to target intracellular biomarkers for therapeutic applications.
Biography
Kyung Oh Jung has completed his PhD in 2016 from Seoul National University College of Medicine, studying about the concepts of molecular imaging and tumor
biology. He is a Post-doctoral fellow from Stanford University School of Medicine from September 2016.
Kyung Oh Jung, J Nanomed Nanotechnol 2016, 7:4 (Suppl)